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Thoracic duct drainage (TOO) was established for 21-115 days 
in 40 kidney recipients with an average removal per patient day 
of 4.7 I lymph and 1.88 billion cells. Cellular and humoral 
immunity were depressed. TOO and immunosuppressive drugs 
were started at transplantation in 35 recipients of cross-match 
negative grafts. Althougb the results were better than in 
precedent non-TOO controls, eight patients rejccted their 
~~rafts before a full TOO effect, and three of the eight developed 
predominantly anti-B lymphocyte cytotoxic antibodies which 
were probably responsible for positive cross-matches with their 
next donors. With continuing TOO, all eight patients had good 
initial function after early retransplantation. In five more 
"non transplantable" patients with performed cytotoxic anti-
bodies, TOO was started 30-56 days before transplantation. In 
these five pretreated patients, antibodies persisted with positive 
antidonor cross-matches. Hyperacute rejection occurred 
repeatedly in two patients with high anti-T (and anti-B) titers, 
but was surmounted in three patients with lower titers. From 
the clinical and immunologic data, we have concluded that TOO 
should be used for pretreatment of all cases with or without 
prior antibodies, and have suggested an adjustable management 
plan that takes into account new developments in antibody 
monitoring. 
THE IMPERFECTIONS of immunosuppression for re-
nal transplantation are well known, particularly 
when cadaveric donors are used. 46 Treatment often 
does not control rejection on the one hand, or is ex-
cessively dangerous on the other. The consequence 
is that renal transplantation has not lived up fully to 
the optimistic expectations of a decade or longer ago, 
a fact that increasingly has clouded the proper rela-
tionship between transplantation and its alternative. 
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We report here a clinical trial of renal homotrans-
plantation using thoracic duct drainage (TDD) as an 
adjunct to standard immunosuppressive therapy. The 
rationale for such an approach was provided by the 
classical investigations by Gowans and his associates 
in rats. 12 ,24,25 TDD apparently was first tried clinically 
in 1963 in Saint Louis by Newton and later in Stock-
holm by Franksson. However, Newton's attempt was 
not described until 1965,30 nearly a year after Franks-
son's first report. ~ 
The present report will document an apparent im-
provement of early results in patients who had TDD 
begun contemporaneously with transplantation or in 
some cases before. The clinical and immunologic stud-
ies of these patients have suggested that adjustments 
in the timing of TDD could make this' procedure even 
more valuable, and can permit some transplantations 
to proceed in the face of the kind of anti-donor cyto-
toxic antibodies that ordinarily cause hyperacute kid-
ney rejection. 
Methods 
Case Material 
TDD was used in 40 patients as an adjunct to classical 
immunosuppression. Daily azathioprine doses were 
started on the day of transplantation and kept as high 
as possible without causing leukopenia. The eventual 
amount given usually was 1-2 mg/kg/day. Prednisone 
was started at the time of operation at a dose of 3-5 
mg/kgand subsequently reduced by 10-20 mg/day until 
a level of about 1 mg/kg was reached. Further reduc-
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tions were variable and were determined in part by 
evidence for or against rejection. Antithymocyte glob-
ulin (ATG) was given intravenously to 26 patients 
who had no prior sensitization to equine protein. The 
ATG doses were approximately 10 mg/kg/day for 14 
days, and 10 mg/kg every other day for an additional 
2 weeks. Some of the ATG courses had to be shortened 
because of sensitivity reactions to equine protein. 
The use or omission of ATG was not thought to be 
an important factor in either the TDO cases or the 
retrospective controls with which they were compared. 
When producing our own antilymphocyte globulin 
(ALG), our cadaveric graft survival was improved. 43 •46 
However, during the last several years while using a 
commercial ATG in a clinical trial, there has been no 
difference in results with or without this agent. 
Approximately half of the recipients had splenec-
tomy prior to transplantation. A few more had sple-
nectomy after transplantation because of persistent 
leUkopenia which precluded effective treatment with 
azathioprine. 
The 40 patients who had TOO were consecutive; 
follow-ups of 5-121,/2 months are available. They were 
divided into the categories described below. 
Group I: living related transplantation. Primary re-
nal transplantation was performed in five patients who 
were 16-30 years old (average 25). One recipient had 
a fully matched sibling donor. The other 4 had maternal 
(3 examples) or paternal (1 example) donors of whom 
each had two HLA antigen mismatches with the 
recipients. 
Group II: primary cadaveric transplantation. The 25 
patients were 11-55 years old, average 35. They had 
few HLA matches with their donors, averaging only 
0.96 out of the possible 4. Five of the recipients were 
diabetic, and all five were considered to be poor risk. 
Group III: cadaveric retransplantation. These five 
patients averaged 40 years of age (range 20 to 54), and 
had previously rejected one (2 examples), two (2 ex-
amples), and four (one example) homografts from 15 
months to 6 years previously. One patient's donor had 
3 HLA matches, one had 2 matches, and 3 had one 
match only. 
Group IV: cadaveric transplantation against pre-
formed antibodies. Five patients, aged 15-38 years, 
had high titers of cytotoxic antibodies against lympho-
cyte panels. Furthermore, the recipients' sera had 
provided positive cytotoxic cross-matches against all 
organ donors obtained at our center during periods 
ranging from two months to three years. Consequently, 
these five patients were considered nontransplantable 
by conventional criteria. They were pretreated with 
TOO and given kidneys from cytotoxic cross-match 
positive donors. In all ten transplantations performed 
in these five patients, the recipients' sera killed more 
than 90% of the donor lymphocytes. 
Three more patients, one from Group II and two 
from Group III, rejected cadaveric grafts and devel-
oped antibodies while on TOO which had been started 
on the day of transplantation. TOO was continued and 
retransplantation was carried out despite the persistence 
of anti-donor antibodies. 
Thoracic Duct Drainage 
Technique and management. The thoracic duct was 
cannulated in the left neck, except for two patients 
whose thoracic duct was approached intrathoracically 
at the T5 level by a right thoracotomy through the 
fifth intercostal space. Into the duct was placed a 
Number 4-7 Swan-Ganz double-lumen catheter after 
cutting off the balloon. For the cervical insertion, the 
important step of passing the catheter into the upper 
mediastinum was aided by dilating narrowed segments 
(usually at valve sites) with metal probes. Postopera-
tively, heparinized saline (1000 units heparin in 500 ml 
saline) was infused at about 20 ml/hour through one 
lumen, and lymph was collected from the other lumen 
into a dry plastic transfer pack. * The small amount 
of heparin prevented clotting during subsequent cen-
trifugation, transfer of the cell-free fluid to the ap-
pendage bag, and intravenous reinfusion. A day's col-
lection of processed lymph was reinfused continuously 
throughout the following day. A narrow spectrum anti-
staphylococcal antibiotic was given systemically after 
several of the early patients developed staphylo-
coccal bacteremia. 
The daily volumes of lymph were recorded as well 
as the lymph cell counts. The differential composition 
was determined after Wright staining and in some 
samples after nonspecific esterase staining.55 From this 
information, the daily and total numbers of lympho-
cytes removed could be computed. 
It was found that the costs of TOO could be reduced 
drastically. Initially, the volume differences between 
collected and processed lymph were made up with 
plasma. This was found to be unnecessary. In fact, 
we have recently found that the lymph sometimes could 
be discarded for weeks or months on end without ad-
verse effects providing adequate volumes of electrolyte 
solution were given intravenously. Under these cir-
cumstances, even the collection bags became un-
necessary. The containers for the intravenous solutions 
were transferred when they were empty to the floor 
and reused as receptacles for the discarded lymph. 
* Special transfer packs for TDD are available from the Fenwall 
Corporation, Deerfield, Illinois. These have a collectIOn capacIty of 
600-700 m\. 
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A few of the lymph fistulas failed spontaneously but 
usually active efforts were required for discontinuance. 
The collection bags were gradually raised to slow the 
lymph flow. After lymph output finally stopped, the 
cannula was pulled out. A pressure dressing was ap-
plied to the supraclavicular triangle. 
Timing. In Groups I-III, TDD was started at the 
time of transplantation and continued for at least 40 
days if possible. If the first homograft was rejected, 
the period of initial failure was considered pretreatment 
for a second try for which drainage was continued (Fig. 
1). The shortest period of drainage in Groups I-III 
was 21 days, and the longest was 115 days. 
The five patients of Group IV with preformed cyto-
toxic antibodies had TDD started from 30 to 55 days 
before transplantation. The lymph was discarded and 
30,000 
BLOOD 20,000 
WBC 
mm3 10,000 
e-
o 
replaced with plasma or electrolyte solution in the first 
two patients. Cell free lymph was reinfused in the other 
three for the first 30-40 days and discarded subsequently. 
The three additional patients from Groups 11 and III 
who developed posttransplant antibodies while on 
TDD had their retransplants 28,90, and 106 days after 
institution of the lymph fistulas. TDD was still in effect 
in the first and third of these patients. The catheter 
had clotted a few days before retransplantation of 
the second patient. 
Immunologic Studies 
Cells removed. Cells from the thoracic duct lymph 
and from peripheral blood were separated by density 
gradient centrifugation on Ficoll-Hypaque. 4 T-cells 
were identified by the direct E-rosette technique using 
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FIG. I. Prompt retransplantation under TDD. The first kidney was rejected in two weeks, but the second organ transplanted after 26 days 
of TDD functioned perfectly. Note the slow increase in lymph drainage per day and the variable numbers of cells removed per day. The 
lymphocyte differential percentage was somewhat reduced during TDD, but because of the variable total white blood count the absolute 
number of circulating lymphocytes was not much changed. 
Vnl. 190. No.4 LYMPH DRAINAGE AND TRANSPLANTATION 477 
sheep erythrocytes.a B-cells were identified by their 
surface immunoglobulin, as demonstrated with fluores-
cinated antipolyvalent immunoglobulin. 36 Data was re-
ported as percent T- and B-cells per total lymphocytes. 
Cellular immunity. Before TDD or other immuno-
suppression, skin test reactivity in 25 patients was 
tested with PPD, tetanus, streptokinase-streptodornase 
(SKSD), trichophyton, and candida. Nonspecific reac-
tivity was determined with croton oil applications. The 
tests were repeated after 21 days of TDD, and again 
two weeks after TDD was discontinued in those cases 
in which the initial tests had been positive. The lym-
phocytes from four patients who were SKSD positive 
were studied in vitro for blast transformation after ex-
posure to the antigen.:35 The nonspecific mitogenic 
responses to phytohemagglutinin and concanavalin A 
were determined in vitro of the lymphocytes of 11 of 
the 25 patients. 35 The 11 included four who had at 
least one positive skin test and seven more whose skin 
tests were all negative. 
Humoral immunity. Twenty-four of the same 25 pa-
tients were screened by a hemagglutinin inhibition test5 
for serum antibodies to AlVictoria and B/Hong Kong 
influenza. Twenty-two (92%) had preexisting antibodies 
to AlVictoria and 11 (46%) had anti-B/Hong Kong 
antibiodies. All 25 patients were then given intramus-
cular bivalent vaccine* five days after institution of 
TDD. Antibody response to the vaccination was de-
termined 21 days later. 
Serum immunoglobulins. Serum and lymph IgG, 
IgM, and IgA concentrations were measured with 
radial immunodiffusiont before, during and after TDD. 
Serologic studies. HLA typing, direct cross-match 
testing, and panel cross-matches were with standard 
techniques. 47 The panels of 37 -42 donors were selected 
to provide a representative cross section ofHLA types. 
B- and T-Iymphocytes were isolated by nylon wool 
column. 47 Five to eight serial 1:2 dilutions of the sera 
were tested simultaneously against a panel of 22-35 
normal individuals. The incubation temperature with 
antibody was either at 5° or at 37°. Incubation with 
complement was at 25°. Incubation times were one hour 
with the serum and two hours with complement. 
Results 
Reliability and Safety of TDD 
During accumulation of the series of 40, attempts 
at TDD failed in two other patients. Thus, the success 
rate in establishing TDD for at least 21 days was 95%. 
In both of the failures, the cervical thoracic duct could 
not be located despite extensive dissection. In two of 
the 40 successful cases, the thoracic duct eventually 
* Parke Davis and Company, Detroit, MI 48232. 
t Kallestad Laboratories, Inc., Chaska, MN 55318. 
was cannulated in the right thorax through a fifth inter-
costal space incision. This approach was used for one 
patient after the cervical attempt had failed. The other 
patient's cervical TDD stopped draining after 98 days 
and the thoracic reoperation was an attempt at 
continuation. 
There was no mortality from TDD per se. The most 
significant complication was in the patient with pre-
formed antibodies whose cervical TDD failed after 98 
days. The thoracic duct was recannulated in the right 
thorax, but satisfactory drainage could not be obtained. 
She developed an empyema which eventually required 
thoracotomy and decortication. 
Minor complications included local lymph accumula-
tions in the neck, transient edema of the face or left 
arm, temporary Horner's syndrome in two patients, 
one example of transient right chylothorax following 
removal of the cannula, and one retained subcutaneous 
catheter which was removed later. Four of the first 
patients developed staphylococcal bacteremia, a com-
plication which was prevented in almost all subsequent 
cases by the prophylactic administration of narrow 
spectrum antistaphylococcal antibiotics. 
TDD Volumes and Cells 
Quantities drained. The 40 TDDs were in place for 
58.4 ± 3.5 (S.E.) days (range 21-115). Pooling all 40 
patients and all days of drainage, the lymph obtained 
per patient per day was 4690 ± 240 (S.E.) mllday. 
There was considerable variation from patient to pa-
tient in the lymph collected, and even in some indi-
vidual patients from day-to-day (Figs. 1 and 2). The 
lowest average daily production was 1710 ± 24 (S.E.) 
ml/day in a patient whose fistula drained for 30 days. 
The highest output was 7670 ± 210 (S.E.) mllday from 
a patient whose drainage lasted for 84 days. 
Cells removed. Pooling all 40 patients and all days of 
drainage, the numbers of cells removed per patient day 
was 1.88 ± 0.19 x 109 (S.E.). In about two-thirds of 
the patients, there was a progressive decline of the cells 
removed (Fig. 2), but in the others the source of 
lymphocytes seemed inexhaustible (Fig. 1). More than 
98% of the cells were classified as small lymphocytes by 
Wright staining and morphologic criteria. However, 
with nonspecific esterase staining some of the cell 
collections had as many as 25% monocytes. The 
percentage of Tand B-lymphocytes in the total cell 
collection was variable, but in most cases the selective 
T-cell depletion described by Machleder and Paulus22 
was not seen. These observations were similar in 
patients with TDD alone and in those in patients studied 
during multiple agent immunosuppression including 
TDD. 
Nor was there a uniform effect on peripheral blood 
lymphocyte total counts and differential percentages 
478 ST ARZL AND OTHERS Ann. Surg. 0 October 1979 
1:8 
TITER OF ANTIBODIES 14 
WARM Anti - B <>----<> 12 
WARM Anti - T -----
1:1 
0 
30,000 
BLOOD 
WBC 
20POO 
mm3 10POO 
0 
8,000 
6,000 
LYMPH 
ml/day 4,000 
-- 2,000 
0 
50 
BUN 
... 
a: 01 <to 
...... 
(J) 
>-
:::E 
o 
... 
u 
w 
z 
W 
...J 
a. 
(J) 
.. 
17 yo d 
wI 67kg--+ 67kg 
DAYS 
9 CELLS 
lOx 10 REMOVED 
PER DAY 
mg% 25 f----- -- HEMODIALYSIS --------1 
ATG 0 
600 mg per dose 150 
AZATHIOPRINE 100 50 
mg/day 0 
PREDNISONE 100 
mg/day 
200 
-50 -40 -30 -20 -10 0 10 20 30 40 
TIME IN DAYS 
FIG. 2. Pretreatment by TDD in a patient with preformed cytotoxic antibodies. Warm anti-T lymphocyte and anti-B lymphocyte antibodies 
were still present in the recipient serum at the time of transplantation but these were of low titer. Nevertheless. there was a completely 
killing positive cytotoxic crossmatch against the donor. Hyperacute rejection did not occur. 
although the lymphocyte fractions were often reduced 
(Fig. O. 
Immunologic Studies 
Serologic studies in 8 patients who were given kid-
neys despite positive cross-matches with their donors 
are given later with the Group IV clinical results. A 
number of patients had less specific immunologic 
assessment. 
Cellular Immunity. There were only nine positive 
skin tests in 6 patients among 25 examined preoper-
atively. These included one positive reaction for PPD, 
two for tetanus, four for streptokinase-streptodornase 
(SKSD), two for candida and none for trichophyton. At 
the same time, nonspecific reactivity was demonstrable 
with croton oil in 24 of the 25 patients. Three weeks 
after starting TDD, all except one of the nine positive 
skin tests had become negative; the 24 positive croton 
oil tests remained positive. The specific skin tests 
converted to negative both in patients treated solely 
with TDD and in patients who were concomitantly 
started on double- or triple-agent immunosuppression. 
Two weeks after discontinuance of TDD, none of the 
eight negative skin test conversions had returned to 
positive. Four patients whose SKSD skin tests 
disappeared also lost in vitro SKSD induced blast 
transformation of their lymphocytes. 
As TDD and other immunosuppression proceeded, 
responsiveness to phytohemagglutin and concanavalin 
A was retained by the lymphocytes of all 11 patients 
among the foregoing 25 who were tested. 
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Humoral immunity. Only six (25%) of the 24 patients 
tested responded to immunization with a significant 
increase, and in only one of these was the response 
to both flu strains. Three of the patients (12%) lost 
pre-existing antiflu antibodies during the first three 
weeks of TDD. 
Serum immunoglobulins. As reported before,42 im-
munoglobuiins invariably fell during TDD combined 
with multiple agent immunosuppression. However, 
this could have been due in part to azathioprine, 
prednisone and A TG. 
The objection did not apply for the five patients pre-
treated solely with TDD for cytotoxic antibodies. TDD 
alone caused drastic reductions in IgG, and less ex-
treme reductions in IgM and IgA (Table 1). The changes 
were the same without (cases 1 and 2) and with (cases 
3-5) lymph reinfusion. After discontinuance of TDD, 
the immunoglobulins rebounded to or above previous 
levels even though azathioprine and prednisone were 
in effect by this time (Table 1). 
Mortality From Transplantation 
Two (5%) of the 40 recipients died. One patient 
perforated his ileum eight weeks after transplantation 
and died 1 Y2 months later with uncontrolled intra-ab-
dominal infection. The second patient developed pan-
creatitis, pneumonitis (due to Pneumocystis carinii) 
and a cerebrovascular accident. She died five months 
posttransplantation. 
Outcome in Subgroups 
Group I: Living related transplantation. Starting on 
the day of transplantation, TDD was used for 34-78 
days. All five of the recipients have life-supporting 
homografts after six, seven, nine, 11 and 12 months. 
Renal function is normal in four cases. The fifth patient 
has a serum BUN of 60 mg/dl and a serum creatinine 
of 2.5 mg/dl, 11 months after transplantation. This pa-
tient had TDD for only 34 days. 
We have obtained satisfactory results in similar past 
cases without TDD.46 Of the comparable consanguine-
ous nonmatched recipients treated just prior to the 
TDD series, four still have good function of their origi-
nal grafts with follow-ups of 12-22 months. The fifth 
retrospective control patient rejected his perfectly 
matched sibling graft in two weeks. 
Group II: Primary cadaveric transplantation. The 25 
patients had TDD for 21-92 days, starting on the day 
of transplantation. One recipient died after 5Y2 months 
for a mortality of 4%. By five months, two additional 
recipients had been returned to dialysis. One de-
clined a second try at transplantation under continuing 
TDD. A second homograft was placed in the second 
patient, but had to be removed because of an arterial 
suture line infection and acute hemorrhage while it was 
still functioning normally. 
Six other patients rejected their first cadaveric kid-
neys in ten days to two months. Second homografts 
were placed within a few days or weeks under con-
tinuing TDD (Fig. 1). All of the second grafts functioned 
promptly. 
By five months, 16 (64%) of the 25 recipients re-
tained their original grafts and had good to normal renal 
function. The six patients (24%) who had prompt re-
transplantation when the first organs were rejected 
were also free of dialysis. Thus, 22 (88%) of the 25 
cadaveric recipients reached five months with graft 
function. The results were better than in our reported 
past experience46 and superior to that with an immedi-
ately precedent series of 25 similar cadaveric cases 
(Fig. 3). In the retrospective control group, the mor-
tality by five months was 20%. Thirty-two per cent 
of the patients were back on dialysis. The incidence 
of patients with a successful first graft was 44%. In-
cluding one additional patient who had early retrans-
plantation, the number of patients with adequate renal 
function was 48%. The improved overall five month 
success rate (88 versus 48%) was significant (p < 0.01). 
The improved record (64 versus 44%) with first grafts 
did not reach statistical significance. 
Rejection after five months was troublesome both 
in patients of the TDD and control series. In the TDD 
group, 24 patients are alive after five to 12Y2 months 
but one primary homograft has stable chronic rejection 
at 1OY2 months. Two of the retransplants are presently 
being lost in the sixth month. In the control series, 
late losses occurred after six and eight months, the 
latter due to death. 
Group III: cadaveric retransplantation. These five 
TABLE 1. Immunoglobulins (mgldl) Before, During and After TDD in Group IV Patients 
S.B. D.F. G.F. S.A. R.G. 
Patient G M A G M A G M A G M A G M A 
Before TDD 1050 81 66 540 120 198 900 48 360 1450 255 235 1240 250 200 
Lowest During TDD 163 24 36 141 29 38 190 18 37 360 78 42 350 80 38 
1-4 Months Post-TDD* 850 76 54 680 100 120 645 198 200 925 145 245 1450 98 65 
* Azathioprine and prednisone being given. Values before and during TDD were without other immunosuppression. 
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FIG. 3. Results after five months in 50 consecutive recipients of 
first cadaveric transplants. Twenty-five had TDD and 25 did not. In 
the TDD group. lymph drainage was continued if the primary kidney 
was rejected. A second attempt at transplantation was made 
promptly (Fig. I). 
patients had TDD for 25 -105 days, starting at the time 
of transplantation. By five months, one patient had 
died of bowel perforations, and one was back on dialy-
sis. The three other (60%) had life-supporting renal 
function, in one case after retransplantation following 
rejection of the first organ. Two of the three patients 
still have life-supporting function after seven and ten 
months, but one of these grafts has had several late 
rejections. The third patient rejected his kidney after 
nine months and returned to dialysis. 
Our reported past experince was poor with cadaveric 
retransplantation in previously failed cases. 16 In five 
cases immediately preceding the TDD trial, there was 
one death and two returns to dialysis within five 
months. Thus, in this small group, there was no signif-
icant difference with or without TDD. 
Group IV: cadaveric transplantation against pre-
formed antibodies. Two of the five patients with pre-
formed cytotoxic antibodies escaped hyperacute rejec-
tion (Fig. 2). Their kidneys are still functioning well 
after 5Y2 and eight months. The first kidney of a third 
patient was placed after 30 days of TDD. It did not 
function well and had to be removed 19 days later 
because of its severe platelet sequestration which re-
sulted in a thrombocyte count of 5000 mm3 • A second 
homograft was placed in this patient after 15 more days 
of TDD (total 45 days). Despite a positive cytotoxic 
cross-match, it functioned normally for six months, 
but then underwent a subacute rejection that has been 
difficult to control with increased steroid doses. The 
fourth and fifth patients hyperacutely rejected four and 
two grafts, respectively. They were returned to dialysis. 
The serologic findings in the five patients who had 
preformed antibodies before TDD are summarized in 
Table 2. The lymphocytes of all ten donors for the 
five recipients were completely killed by the serum of 
the recipient in question. However, with panel analysis, 
the anti-T -cell antibodies in the three patients who had 
successful transplantation (cases 1-3) started at low 
titers and tended to drift down during pretreatment 
with TDD (Figs. 2, 4 and 5). One kidney which was 
transplanted when the anti-T antibody titer was only 
1: 1 underwent delayed hyperacute rejection. At the 
same titer (Fig. 5), a subsequent transplantation suc-
ceeded. All kidneys transplanted when anti-T cell titers 
were greater than 1:4 were hyperacutely rejected (Fig. 
6). All five patients also had warm anti-B lymphocyte 
antibodies during TDD or at the time of transplanta-
tion. After transplantation, the warm anti-T and anti-B 
antibodies remained detectable in two of the successfully 
treated patients, but eventually at a reduced level (Figs. 
2, 4 and 5; Table 2). In the unsuccessfully treated pa-
tients 4 and 5, warm anti-T and anti-B antibodies re-
mained high or rose even higher after the hyperacute 
rejections (Figure 6, Table 2). Cold anti-B antibodies 
were not present before transplantation in any of the 
five cases and appeared postoperatively in only one 
patient (Fig. 2). 
Three additional patients from Groups II and III had 
rejected kidneys and developed antibodies while on 
TDD. On direct cross-match their sera incompletely 
killed the lymphocytes of their second donors. With 
panel analysis at that time, two of the three patients 
had low anti-T titers of 1: 1. All three patients had warm 
anti-B antibodies (1:1 to 1:16). The changing serum 
antibody conditions in one of these patients before, 
during and after TDD and two transplantations is 
shown in Figure 7. 
Discussion 
Standard immunosuppression worldwide has been 
with azathioprine and prednisoneI5 ,27,4o,44,54 to which 
heterologous antilymphocyte globulin (ALG) may be 
added. 29 ,41.43 Cyclophosphamide can be substituted for 
azathioprine. 45 Prednisone is the only highly adjustable 
component of these so-called double and triple drug 
programs, but despite massive steroid therapy, failure 
to control early rejection has been distressingly com-
mon. With related but imperfectly matched donors, 
the one year kidney survival in large cooperative series 
has hovered at about 70%.34 In a survey of 4474 recipi-
ents of first cadaver grafts treated in 195 American 
transplantation centers between 1971 and 1976, Opelz, 
Sasaki, and Terasaki34 recorded a 45% kidney loss rate 
at six months and a 55% loss rate at one year. Isolated 
centers including our own here reported somewhat 
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TABLE 2. Group IV Patients with Positive Antidonor Cross-Matches 
Patient 
Transplant No. 
Per cent of kidney donor 
lymphocytes killed by 
patient serum (direct 
crossmatch) 
Per cent Anti-TAbs 
(panel crossmatch) 
just pre-transplant 
Duration TDD before 
transplantation (days) 
Titer Anti-TAbs 
Highest pre-TDD 
Just pre-XP 
Mean post-XP 
Titer Warm Anti-B Abs 
Highest pre-TDD 
Just pre-XP 
Mean post-XP 
Per cent Cold Anti-B Abs 
Highest pre-TDD 
Highest post-XP 
Outcome 
S.B. 
1st 
>90% 
48% 
30 
1:4 
1: I 
NA 
1:32 
1:32 
NA 
0% 
0% 
Delayed 
hyperacute 
rejection 
D.F. 
2nd 1 st 
>90% >90% 
NA 92'7< 
45 49 
1:4 1 :5 
I: I 1:3 
I: 1 neg 
1:4 1: 12 
1:32 1:8 
I: 16 neg 
0% 0% 
0% 23% 
Function- Function-
ing ing 
8 mos 8 mos 
NA = not available. Abs = antibodies. XP = Transplantation. 
better results particularly with the use of high potency 
ALG ,29,4R careful case selection,:lH or scrupulous tissue 
typing,32 but the spector of a 50% unfavorable outcome 
has been faced by recipients of first cadaver kidneys 
in most centers. Early or delayed retransplantation in 
such cases has been even less satisfactory, 2.16 
TRANSPLANTATION 
! 
%8 COLD Ab 0 0 0 0 0 0 12 16 
1:16 
1:8 
TITER 
Worm Anti T Ab 1:4 
-------Worm Anti 8 Ab 
0----0 1:2 
1:1 
5 
G.F. 
1st 
>90% 
35% 
43 
1: I 
I: I 
I: I 
1:0.5 
1:2 
I: 1 
0% 
0% 
Function-
ing 
5 mos 
S.A. 
1 st 2nd 3rd 4th 
>90% >90% >90% >90% 
75% 75% NA NA 
55 58 61 88 
1:16 1: 16 1: 16 1: 16 
1:4 NA 1:8 1:8 
NA 1:2 1:8 1:8 
1:32 1:32 1:32 1:32 
1:8 NA 1:32 1: 16 
NA 1:4 1: 16 1: 16 
0% 0% 0% 0% 
0% 0% 0% 0% 
Hyperacute Rejections (4) 
R.G. 
2nd 3rd 
>90% >90% 
92% 100% 
55 72 
NA NA 
I: 16 1:64 
1:64 NA 
NA NA 
1:32 1: 128 
1: 128 NA 
0% 0% 
0% 0% 
Hyperacute 
Rejections (2) 
TDD was added to our treatment protocol in an effort 
to improve this situation, After its introduction clini-
cally by Franksson in 1964,9 TDD as an adjunct to 
azathioprine, prednisone and, in some cases, ALG, 
was given clinical trials in Stockholm,lO,l1 Boston,28,49 
Galveston,8,37 and Lyon.1,50 Since all of these reports 
OF 38 y.o. ~ 
23 9 o o 
KiIKKKKKKKI--Ir--q"---K--~~~:::====~~ !---.. . o i~1 ==~T=---~1~----~¥ 
DATES 6/27178 7/5 7113 7/28 8110 8/25 9/8 9/22 10117 11128/79 1116 2115 3/29 t THORACIC DUCT FISTULA j 
FIG. 4. Antilymphocyte antibodies in a patient pretreated with TDD for 49 days. Note that the anti-T antibody titer was relatively low at 
the time of successful transplantation. 
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D£4~ 
1:32 
1:16 
TITER 
torm~ Ab l:8 
Worm Anti B Ab 
c>--o 
1:4 
1:2 
1:1 
o-jl--j 
TRANSPLANTATION 
2 
1 1 
S8 15 y.o· ~ 
FIG. 5. Antilymphocyte an-
tibodies in a patient pre-
treated with TOO. The first 
homograft underwent a de-
layed hyperacute rejection. 
The second one escaped 
this fate. Note the per-
sistence of antibodies after 
transplantation. The pa-
tient who is now eight 
months postoperative is 
slowly losing her kidney 
after an initial period of 
normal function. 
0 I--rI ~ ~~---r--~--~~-------KI---I---~f I I 
DATES 8/10176 9/9177 7110178 7128 8/10 9/1 10/13 10/17 1113 1/23179 2115 3/29 
t THORACIC DUCT FISTULA j 
claimed a benefit from TOO, especially in cadaveric 
cases, it was surprising that the efforts were abandoned. 
The most important reason apparently was the inability 
to consistently obtain effective lymph drainage, an ob-
jection that was almost completely eliminated in our 
trial. Annoyance to the patients and expense were other 
factors. In addition, clinical reports from Italy ,23 
Brazil,17 and Japan39 were considered discouraging 
even though the quality and duration oflymph drainage 
were suboptimal. 
Only Walker and Johnson and their associates at 
Vanderbilt persisted.20,31,52 In 1977, they described the 
use of TOO for about one month to prepare 50 poor 
risk patients for cadaveric kidneys. The graft survival 
two to five years later was almost 75%, nearly twice 
as good as in a control group. The propriety of pre-
treatment has been supported by the observations of 
Machleder and Paulus22 who used TOO as the sole 
immunosuppressive treatment of autoimmune diseases 
such as rheumatoid arthritis and scleroderma. Mach-
leder and Paulus22 recently delineated in humans the 
time curves for suppression of humoral and cell-medi-
ated immunity, greatly extending the observations of 
a number of earlier investigators.1,6,8,13,37.51 The demon-
12 
TRANSPLANTATION 
3 4 
TITER 
Warm Anti T Ab 
....---
1:32 
1:16 
1:8 
1:4 
Warm Anti B Ab 
0---0 
1:2 
1:1 
SA 20 y.o. ~ U 1 1 
l~------------D---r-r-~-----nMrl Df----Df-rl~~r-------~~ 
DATES 917178 10/24 11/611114 11127 yl-y~mD~ 114179 Iy~~~lgOfT 2116 3/20 3/29 
t THORACIC' DUCT FISTULA t 
FIG. 6. Antilymphocyte an-
tibodies in a patient who 
hyperacutely rejected four 
kidneys in spite of pre-
treatment with TOO. Both 
warm anti-T and anti-B 
antibodies remained high 
throughout. The presence 
of high titer anti-T -lympho-
cyte antibodies would dis-
suade us from making fu-
ture transplantation at-
tempts until these could 
be lowered. 
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FIG. 7. Antibodies in a patient who had rejected four kidneys prior to TDD. TDD and transplantation were performed at the same operation. 
Note the brisk antibody response to this homograft which was promptly rejected. The second and successful transplant was carried out 
after 106 days TDD. 
stration of humoral antibody suppression with TDD 
was particularly important since it confirmed earlier 
claims by Tunner et al. 51 and Graber et alY that had 
been denied by otherslK~I:1TIRM in spite of the incisive 
animal work by McGregor and Gowans. 24 In humans, 
substantial immunosuppression required three weeks 
and the full effect of thoracic duct drainage as the only 
immunosuppressive device was not established until 
30 days. Although less extensive, our own immuno-
logic data herein reported were compatible with those 
of Machleder and Paulus. 
TDD in our trial was used differently in that TDD 
usually was instituted at the time of transplantation 
instead of preoperatively. Pretreatment in patients 
without antibodies was omitted because of the unpre-
dictable availability of cadaveric organs and because 
of our subsequently allayed fear that TDD could not 
be maintained throughout long waiting periods. How-
ever, the foreseeable penalty was the irreversible rejec-
tion of several kidneys during the "uncovered" first 
three or four weeks. The corollary policies which we 
accepted were to consider these periods of graft loss 
as pretreatment for a subsequent organ, and to main-
tain thoracic duct drainage until retransplantation. Eight 
retransplantations were performed with these condi-
tions and none of the grafts was rejected acutely; only 
one kidney was lost early and that because of delayed 
hemorrhage from an infected renal arterial suture line. 
Under ordinary circumstances, such early retrans-
plantation in past experience has often been futile and 
sometimes dangerous. 2,14,16 
A probable beneficial influence of thoracic duct 
drainage used in this way was evident in the 30 patients 
without preformed antibodies who were submitted to 
transplantation for the first time and who have been 
followed for 5-13 months. These included five recipi-
ents of consanguineous grafts, of whom all have stable 
renal function. After five months 22 (88%) of25 primary 
cadaveric recipients have life-sustaining renal function 
either with their first (64%) or promptly inserted 
back-up (24%) graft. At five months the results in the 
25 cadaveric cases were almost twice as good as in 25 
immediately precedent and similar controls not treated 
with TDD. 
In spite of these findings, we now recommend TDD 
pretreatment. The need for so many back-up grafts has 
been unnecessarily wasteful of organs, to say nothing 
of the emotional trauma and extra risks imposed on 
the recipients. One discouraged patient withdrew from 
consideration for a replacement graft. In another case, 
the infection which necessitated removal of a perfectly 
functioning second transplant probably originated from 
the rejected primary graft. 
Moreover, the immune reaction during the un-
covered first several weeks was vigorous enough not 
only to cause several graft rejections but to permit, 
as well, a potentially harmful antibody response which 
was thought in retrospect to be anamnestic in some 
patients with prior but undiagnosed sensitization. The 
ability to perform retransplantation in such cases in 
spite of an antibody storm probably reflected the 
deepening suppressive effect of TDD upon humoral 
as well as cellular immunity. Undetected presensi-
tization has been suspected to be a particularly com-
mon problem in patients undergoing retransplantation 
and this may have contributed to the inferior results 
in this small subgroup of our series. But even in 
those having transplantation for the first time, high 
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immunologic responsiveness with or without a com-
ponent of presensitiz~tkm has long been known to be 
an adverse feature33.53 and one which would be miti-
gated with TDD pretreatment. 
Knowledge of the humoral antibody suppression 
caused by TDD prompted an effort to pretreat five 
patients whose sera contained such broadly ranging 
preformed cytotoxic antibodies that there was little or 
no hope of finding a suitable cadaveric donor. Before 
thoracic duct drainage, all five patients possessed the 
anti-T lymphocytotoxins of the IgG class which are 
associated with hyperacute rejection7.1s.47 as well as the 
less malevolent7,21,26,47 but still harmfu}ls,19 warm anti-B 
antibodies of the IgG class. Cold anti-B IgM anti-
bodies which have been associated with active en-
hancemene,13,47 were not present preoperatively. 
Three of the five recipients had successful trans-
plantation, one by virtue of a second homograft 
after an indolent variation of hyperacute rejection in-
cluding massive platelet sequestration had destroyed 
the first organ. The thoracic duct drainage had not 
eliminated anti-T lymphocytotoxins, and high-kill 
positive cross-matches were present with the actual 
donors. However, the anti-T-cell titers at the time of 
the successful transplantations were at moderate levels 
at the same time as there was profound immuno-
globulin depletion. In the two unsuccessful cases, 
there was equivalent serum immunoglobulin depletion 
by TDD, but the anti-T-cell titers remained high. 
The 60% eventual success rate in the 5 patients 
transplanted despite positive cytotoxic antidonor 
cross-matches was the same as that reported earlier 
after TDD by Niblack et al.31 In future cases, care-
ful monitoring of anti-T-cell cytotoxic antibody titers 
may give a better signal when to proceed. If high 
titers are refractory to thoracic duct drainage, addi-
tional pretreatment with azathioprine, prednisone, and 
ALG will have to be considered as well as removal 
of blood IgG by plasmaphoresis. It is possible that 
discarding the lymph as was done in cases 1 and 2 
expedited antibody depletion. Because replacement of 
discarded lymph with plasma was so expensive, this 
practice was stopped. It has since been learned that 
lymph losses can safely be replaced with intravenous 
electrolyte solutions for long periods. 
The wider use of TDD together with exploitation of 
recent typing advances cited earlier is apt to change 
policies and practices in transplantation. Recipients 
(particularly those needing cadaveric organs) always 
have been ruled by the donors, with the final de-
cision about candidacy hinging mainly on the conven-
tional negative cytotoxic crossmatch and to a minor 
extent on HLA matching. In the future, it seems 
probable that the recipients wishes can be given greater 
weight. As in the past, the first step will be to check 
for antibodies against a lymphocyte panel. If these are 
found, they should be clas<sified as warm or cold anti-T 
or anti-B. With such information, a decision can be 
made about an appropriate duration of TDD pre-
treatment. 
We believe that all recipients should be pretreated 
with TDD with the possible exception of those who 
have perfectly matched sibling donors. We suggest 
TDD pretreatment for about 21 days in recipients who 
have been antibody free or who have cold anti-B 
cytotoxins, and who have a negative conventional 
cytotoxic crossmatch with the donor. Patients possess-
ing warm anti-T and/or anti-B lymphocytotoxins should 
have TDD pretreatment for 30 or 35 days before 
transplantation, even if crossmatch negative donors 
can be found before this time. Patients who have 
crossmatch positive donors after 35 days of TDD can 
have transplantation if the responsible antibody is the 
warm anti-B variety. However, if anti-T antibodies 
persist and are responsible for positive direct cross-
matches, a necessary condition for proceeding would 
be a low titer « 1 :4). If this cannot be achieved with 
TDD alone, pretreatment with other immunosuppres-
sive agents should be considered. 
With successful transplantation, TDD will usually 
be discontinued after a total preoperative plus post-
operative duration of about 60 days. Final upward 
adjustments of prednisone should then be considered. 
Machleder and Paulus22 showed a return of immuno-
logic responsiveness over several months after stop-
ping TDD. Several of our cadaveric recipients who 
were on low maintenance doses of steroids de-
veloped late rejection after stopping TDD, and at least 
two probably will soon lose their homografts. 
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DISCUSSION 
DR. CHARLES THOMAS FITTS (Charleston, South Carolina): The 
problem that Dr. Startzl alluded to early in his abstract and at the 
onset of this talk has been an extra-ordinarily frustrating one to 
transplant surgeons. As immunologists have been unable to provide 
us with an effective and safe method of selective immunosup-
pression, they have turned with prodigious energy and enthusiasm to 
develop a complex array of time-consuming, expensive and fre-
quently unreliable measurements designed to predetermine when a 
kidney transplant will be successful and when it will not. The 
theoretic result of this philosophy is to achieve nearly 100% graft 
survivaL Since this is to be achieved by only transplanting between 
individuals with no significant immune disparity, however, the practi-
cal result will be slowly but surely to decrease the number of patients 
receiving transplants. That should not be our objective. 
What Dr. Starzl has presented here today is a welcome advance in 
attacking the real problem, which is to control the patient's immune 
system to his benefit. He has utilized one of the more predictable and 
reliable tests of the battery that the immunologists have come up with, 
namely, the complement-dependent cytotoxic rematch, to indicate the 
need for a particular type of immunosuppression, rather than as a 
contraindication for transplant. 
(slide) I am doubly pleased that the method successfully used is 
one with which our group had early experience and which our data in 
retrospect would predict its likely success in this situation; that is, a 
predetermined, humorally mediated immunity between donor and 
recipient. In both animal and human studies in the late 1960's, our 
data showed extremely effective abrogation of the humoral response, 
both primary and secondary, as shown here with thoracic duct 
depletion. 
It is my opinion that the benefits will not be limited to this area alone 
but will extend to cellularly mediated problems as well. 
The Vanderbilt transplant group has apparently been finding much 
the same results as reported here today, and I am greatly encouraged 
that a powerful tool, which has been lying around for some time, is 
about to be picked up and put to extremely effective use in 
transplantation. 
DR. ALLAN ELIOT DUMONT (New York, New York): Dr. Starzl 
has shown us clearly, that it is the removal of thoracic duct 
lymphocytes, rather than lymph-borne globulin, that is critical in the 
preparation of these patients for transplantation. 
It is particularly interesting that serum immunoglobulin levels fell 
so rapidly, despite the reinfusion of the antibody-rich lymph. These 
findings are consistent with the idea that thoracic duct lymph includes 
a functionally distinct pool of immunologically competent cells, 
presumably B-cells, which synthesize and release antibody mole-
cules into lymph and into blood. 
In some earlier studies (slide), we found that a number of human 
thoracic duct lymphocytes stained with fluorescein-labeled antibody 
to human gamma globulin. This is a smear of human thoracic duct 
lymph, showing one such positive staining cell. 
Actually, about 4% of thoracic duct lymphocytes contain antibody 
globulin, and this proportion increases rapidly as thoracic duct lymph 
continues to be drained. 
We also found that when these cells are maintained in culture, they 
incorporate labeled amino acids into immune globulin. In patients 
aspects of renal homotransplantation. In Starzl, T. E., (ed.) 
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Saunders Company, 1964, p. 243, 
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Local Radiation and Postoperative Admi ni strati on of an Anti-
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with high titers of cytotoxic antibodies, the kind of Dr. Starzl has 
described to us, specific depletion of these cells may, in fact, be the 
most important effect of thoracic duct drainage, 
DR. JOSEPH E. MURRAY (Boston, Massachusetts): I am reassured 
that Dr. Starzl is focusing his skill and careful study to are-evaluation 
of thoracic duct fistula and drainage. This is a blunt tool which 
deprives the recipient of many of his immune mechanisms, but Dr. 
Stanl has sharpened this tool by his study of its placement in relation 
to the exposure to antigen. 
Some problems with thoracic duct drainage are worth comment; it 
is time consuming, expensive and increases bed occupancy. There 
are additional problems of centrifugation and reinfusion; so it will 
probably not be used by most transplantation centers until it has 
proved its effectiveness. Nevertheless, I am thrilled that Dr. Starzl is 
re-evaluating the technique with his usual care and skill. 
DR. THOMAS E. STARZL (Closing discussion): I agree with Dr. 
Dumont that the removal of the cells, in some way that we do not fully 
understand, and possibly by the mechanism which he described, cuts 
off the immunoglobulin production rather than reducing im-
munoglobulin by its removal from the thoracic duct lymph. 
The amount of immunoglobulin or, for that matter, proteins in the 
thoracic duct lymph is about only half of that in the serum, and so, if 
mechanical removal were attempted, it might be best done by 
peripheral plasmapheresis, since the highest concentration ofIgG is 
there. 
In response to Dr. Fitts and Dr. Murray together, I have the 
impression, more like Dr. Fitts and less like Dr. Murray, that thoracic 
duct fistula is a practical undertaking in terms of cost-effectiveness, 
and even possibly in terms of time invested. At the same time I 
understand perfectly Dr. Murray's concerns from the perspective of 
his trials ten to fifteen years ago. 
In their important pioneering work done in Boston in the I%O's, 
Murray and his associates reported unequivocally improved results 
with thoracic duct drainage, particularly in their experience with 
related cases. It has always been surprising to me that that procedure 
was abandoned at Harvard, Galveston, and some other places. 
In reading back over that early work, I did notice that TOO was 
time-consuming, that it was expensive, and, furthermore, that it was 
a procedure not fully reliable. In the Boston series, failure to achieve 
significant thoracic duct drainage was about 50%, and in the 
Stockholm series of Franksson, the figure was even higher. It created 
a situation in which one could not know for sure what was being 
offered the patient. 
That problem was rectified for us by a young surgeon named Dr. 
Larry Koep, who had the bright idea ofusing a Swann-Ganz catheter 
for the cannulation. He cut the balloon off the Swann-Ganz catheter 
and thus created a double lumen, using one lumen for infusion and the 
other for collection. Exploiting this advance in instrumentation, he 
learned how to advance the catheters into the mediastinum. He had 
solved most of the problems that had confounded the pioneer workers 
with thoracic duct fistula with a technique that had a 95% reliability. 
I do want to make my position clear, while at the same time paying 
tribute to Dr. Murray and those others who worked before. I believe 
that pretreatment with thoracic duct fistulas should be used for all 
patients, related and unrelated, with the possible exception of double 
haplotype identical siblings, and that it will have a broad, and not a 
narrow, use in clinical transplantation. 
